The biliary tree musketeers: cholangiocarcinoma – one name for all, but at least three different diseases with distinct targets-Reference-Cited by-同舟云学术

The biliary tree musketeers: cholangiocarcinoma – one name for all, but at least three different diseases with distinct targets

Published:2024-08-20 Issue:1 Volume:7 Page:
ISSN:2520-8454
Container-title:Surgical and Experimental Pathology
language:en
Short-container-title:Surg Exp Pathol

Author:

Marins Lidiane Vieira^ORCID,Moniz Camila Motta Venchiarutti,Freire Cecília Souza,Campos Antonio Hugo José Fróes Marques

Abstract

AbstractCholangiocarcinoma, a malignant neoplasm of the biliary system, poses a significant challenge in clinical practice due to its increasing incidence and diagnostic and therapeutic complexity. This review addresses the epidemiological aspects, risk factors, and classification of this disease. We examine advances in histological diagnosis, highlighting essential criteria for accurate assessment. Additionally, we discuss standard treatment approaches and their efficacy, alongside the latest innovations in therapy, including emerging biomarkers and targeted therapies. By providing a comprehensive overview of these topics, this article aims to enhance understanding and guide the pathological diagnosis and clinical management of this devastating disease.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s42047-024-00160-6.pdf

Reference82 articles.

1. Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020a;21(6):796–807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13. Erratum in: Lancet Oncol. 2020;21(10):e462. doi: 10.1016/S1470-2045(20)30547-7. Erratum in: Lancet Oncol. 2024;25(2):e61. https://doi.org/10.1016/S1470-2045(24)00013-5. PMID: 32416072; PMCID: PMC7523268.

2. Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020b;21(5):671–684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20. Erratum in: Lancet Oncol. 2024;25(1):e3. https://doi.org/10.1016/S1470-2045(23)00642-3. PMID: 32203698; PMCID: PMC8461541.

3. Adashek JJ, Desai AP, Andreev-Drakhlin AY, Roszik J, Cote GJ, Subbiah V. Hallmarks of RET and co-occuring genomic alterations in RET-aberrant cancers. Mol Cancer Ther. 2021;20(10):1769–76. https://doi.org/10.1158/1535-7163.MCT-21-0329. Epub 2021 Sep 6. PMID: 34493590; PMCID: PMC8492504.

4. Ahn S, Lee JC, Shin DW, Kim J, Hwang JH, High. PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci Rep. 2020;10(1):12348. https://doi.org/10.1038/s41598-020-69366-4. Erratum in: Sci Rep. 2020;10(1):21552. doi: 10.1038/s41598-020-78512-x. PMID: 32704067; PMCID: PMC7378166.

5. Akita M, Fujikura K, Ajiki T, Fukumoto T, Otani K, Azuma T, Itoh T, Ku Y, Zen Y. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol. 2017;30(7):986–97. https://doi.org/10.1038/modpathol.2017.22. Epub 2017 Mar 24. PMID: 28338651.